ClinicalTrials.gov record
Completed Phase 2 Interventional

Alanosine in Treating Patients With Cancer

ClinicalTrials.gov ID: NCT00062283

Public ClinicalTrials.gov record NCT00062283. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 21, 2026, 1:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Intravenous SDX-102 for the Treatment of Patients With MTAP-Deficient Cancer

Study identification

NCT ID
NCT00062283
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Enrollment
Not listed

Conditions and interventions

Interventions

  • L-alanosine Drug

Drug

Eligibility (public fields only)

Age range
13 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2003
Primary completion
Nov 30, 2005
Completion
Nov 30, 2009
Last update posted
Jun 25, 2013

2003 – 2009

United States locations

U.S. sites
12
U.S. states
8
U.S. cities
10
Facility City State ZIP Site status
University of Alabama at Birmingham Comprehensive Cancer Center Birmingham Alabama 35294-3300
Arizona Cancer Center at University of Arizona Health Sciences Center Tucson Arizona 85724
Wilshire Oncology Medical Group, Incorporated - La Verne La Verne California 91750
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical Center Los Angeles California 90048
Lynn Regional Cancer Center West Boca Raton Florida 33428
University of Chicago Cancer Research Center Chicago Illinois 60637-1470
Midwest Cancer Research Group, Incorporated Skokie Illinois 60077
St. Vincent's Comprehensive Cancer Center - Manhattan New York New York 10011
Memorial Sloan-Kettering Cancer Center New York New York 10021
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center Nashville Tennessee 37232-6838
MD Anderson Cancer Center at University of Texas Houston Texas 77030
U.S. Oncology, Incorporated Houston Texas 77060

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00062283, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 25, 2013 · Synced May 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00062283 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →